2252271-93-3
Chemical Structure
Oditrasertib
Synonym(s): SAR443820; DNL788
- CAS 番号: 2252271-93-3
- Formula:C14H15F2N3O2
- Molecular Weight:295.28
IUPAC Name: 4-(3,3-difluoro-2,2-dimethylpropanoyl)-2,3,4,5-tetrahydropyrido[3,4-f][1,4]oxazepine-9-carbonitrile
InChIKey: CSCLQCHKUAMZOY-UHFFFAOYSA-N
SMILES: N#CC1=CN=CC2=C1OCCN(C2)C(C(C)(C(F)F)C)=O
Biological Activity: Oditrasertib (SAR443820) is an orally active, BBB-penetrable and selective reversible inhibitor of RIPK1. Oditrasertib can be used in the research of chronic inflammatory central nervous system diseases, such as amyotrophic lateral sclerosis and multiple sclerosis[1][2][3].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Oditrasertib | 99.02% | Oditrasertib (SAR443820) is an orally active, BBB-penetrable and selective reversible inhibitor of RIPK1. Oditrasertib can be used in the research of chronic inflammatory central nervous system diseases, such as amyotrophic lateral sclerosis and multiple sclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.69
HY-173574RIPK1-IN-31 -
Similarity Score 0.62
HY-162928RIPK1-IN-26 -
Similarity Score 0.53
HY-182720FT108 -
Similarity Score 0.52
HY-162006Pim-1 kinase inhibitor 8 -
Similarity Score 0.51
HY-107617PTIQ -
Similarity Score 0.49
HY-B1316Trimetozine -
Similarity Score 0.49
HY-W792513WAY-620147 -
Similarity Score 0.48
HY-123287Soquinolol -
Similarity Score 0.48
HY-10932Aniracetam -
Explore the MedChemAI to find more analogs
References
- [1]. Fidalgo JDV, et al. Preparation of substituted oxazepines and related compounds as RIPK1 inhibitors and uses thereof. WO2018213632A1. 2018-11-22.
- [2]. Hincelin-Mery A, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024 Jan;17(1):e13690. [Content Brief]
- [3]. Montalban X, et al. Effect of RIPK1 inhibitor, SAR443820, on serum neurofilament light levels in patients with multiple sclerosis: a phase 2 trial design (P6-3.011)[J]. Neurology, 2023, 100(17_supplement_2): 2178.